For the Quarter Ending March 2026
Furosemide Prices in North America
- In United States, the Furosemide Price Index rose quarter-over-quarter in Q1 2026, driven by escalating upstream petrochemical expenses.
- The Furosemide Production Cost Trend increased in March 2026 as the national Producer Price Index rose 4.0%.
- A 3.3% Consumer Price Index increase in March 2026 elevated transportation expenses for domestic Furosemide distribution networks.
- The Furosemide Demand Outlook strengthened during Q1 2026, supported by a resilient 4.0% retail sales growth in March 2026.
- A stable 4.3% unemployment rate and 91.8 consumer confidence index in March 2026 sustained inelastic Furosemide pharmaceutical demand.
- Industrial production grew 0.7% in March 2026, reflecting utility constraints that limited Furosemide active pharmaceutical ingredient synthesis.
- The Manufacturing Index expanded in March 2026, ensuring stable packaging supply and supporting the overall Furosemide Price Forecast.
- Toluene feedstock costs surged in March 2026, while domestic Furosemide oral solution inventories completely depleted in February 2026.
Why did the price of Furosemide change in March 2026 in North America?
- Toluene feedstock costs and upstream petrochemical manufacturing expenses escalated significantly across the market throughout Q1 2026.
- Domestic availability tightened, leading to a recognized Furosemide shortage and depleted inventories in February 2026.
- Expanded pediatric indications and new delivery mechanisms successfully boosted overall Furosemide consumption volumes during January 2026.
Furosemide Prices in APAC
- In China, the Furosemide Price Index rose quarter-over-quarter in Q1 2026, driven by tightening supply and rising feedstock costs.
- The Furosemide Production Cost Trend increased in March 2026 as the Producer Price Index rose 0.5% year-over-year.
- The Consumer Price Index grew 1.0% year-over-year in March 2026, supporting a stable Furosemide Demand Outlook across healthcare.
- Industrial production expanded 5.7% year-over-year in March 2026, ensuring robust basic chemical output for Furosemide synthesis.
- The Manufacturing Index expanded in March 2026, reflecting robust activity and high utilization across pharmaceutical manufacturing facilities.
- Retail sales grew 1.7% and unemployment reached 5.4% in March 2026, shifting consumer preference toward affordable generic Furosemide.
- Consumer confidence hit 91.6 in February 2026, reducing discretionary veterinary spending, which directly impacted the Furosemide Price Forecast.
- Furfural feedstock inventories remained constrained in Q1 2026, while agricultural raw material fluctuations tightened overall market supply.
Why did the price of Furosemide change in March 2026 in APAC?
- Furfural feedstock costs experienced an upward trend in Q1 2026, elevating overall Furosemide production expenses.
- Domestic production faced constraints in Q1 2026 as facilities operated under carefully managed inventory conditions.
- Higher international procurement costs for imported raw materials added upward pricing pressure during Q1 2026.
Furosemide Prices in Europe
- In Germany, the Furosemide Price Index rose quarter-over-quarter in Q1 2026, driven by surging feedstock costs.
- In March 2026, consumer inflation reached 2.7%, increasing operational and utility costs for Furosemide API synthesis.
- Producer prices declined by 0.2% in March 2026, easing upstream cost pressures for basic Furosemide precursors.
- The Manufacturing Index expanded in March 2026, tightening the supply of shared chemical intermediates for Furosemide.
- Industrial production remained stagnant at 0.0% in February 2026, while retail sales grew 0.7%, supporting Furosemide dispensing.
- In February 2026, unemployment stayed at 4.2%, but consumer confidence hit -24.7 in March 2026, impacting premium Furosemide.
- German pharmaceutical industry output plummeted in January 2026, dampening domestic consumption and the Furosemide demand outlook.
- The Furosemide production cost trend increased as toluene and naphtha feedstock expenses spiked during Q1 2026.
- The Furosemide price forecast remained elevated as European import inventories tightened severely throughout March 2026.
Why did the price of Furosemide change in March 2026 in Europe?
- Global toluene and naphtha feedstock costs surged in March 2026 due to upstream energy escalations.
- European chemical import inventories tightened severely in March 2026 amid Middle East supply chain disruptions.
- Domestic availability of chemical precursors tightened significantly in Q1 2026, elevating reliance on regional production.
For the Quarter Ending December 2025
Furosemide Prices in North America
- In United States, the Furosemide Price Index rose quarter-over-quarter in Q4 2025, driven by increasing production costs.
- Furosemide production costs increased in Q4 2025 as natural gas and electricity prices strengthened.
- Overall input costs for Furosemide manufacturing rose 3.0% year-over-year in November 2025, as indicated by PPI.
- General inflation, with CPI up 2.7% year-over-year in December 2025, elevated Furosemide raw material costs.
- Furosemide demand outlook was moderately bullish in Q4 2025, supported by a 4.4% unemployment rate.
- US goods imports and exports of pharmaceutical preparations weakened in October 2025, impacting Furosemide trade flows.
- Industrial production increased 2.0% year-over-year in December 2025, indirectly supporting Furosemide production capabilities.
- Retail sales rose 3.3% year-over-year in November 2025, indicating a strong economy, aiding Furosemide demand.
Why did the price of Furosemide change in December 2025 in North America?
- Furosemide production costs increased in Q4 2025 due to strengthened natural gas and electricity prices.
- Rising input costs for Furosemide manufacturing were evident with a 3.0% PPI increase in November 2025.
- General inflation, with CPI up 2.7% in December 2025, elevated Furosemide raw material and labor expenses.
Furosemide Prices in APAC
- In China, the Furosemide Price Index declined quarter-over-quarter in Q4 2025, driven by weakened overall consumption demand.
- Furosemide production costs decreased in December 2025, as the Producer Price Index fell by 1.9% year-on-year.
- The Furosemide demand outlook remained subdued in Q4 2025 due to decelerated economic growth in China.
- China's Manufacturing Index expanded in December 2025, indicating stable supply chains for pharmaceutical production.
- Industrial Production rose by 5.2% year-on-year in December 2025, reflecting robust manufacturing activity.
- Low retail sales growth of 0.9% year-on-year in December 2025 indicated weak consumer spending and cooled confidence.
- The unemployment rate remained stable at 5.1% in December 2025, supporting consistent healthcare access.
- The Furosemide price forecast indicates continued downward pressure given the prevailing deflationary environment in Q4 2025.
Why did the price of Furosemide change in December 2025 in APAC?
- Overall consumption demand in China weakened during Q4 2025, impacting Furosemide market value.
- Producer Price Index declined by 1.9% year-on-year in December 2025, signaling lower input costs and pricing power.
- Low Consumer Price Index of 0.8% year-on-year in December 2025 reflected subdued consumer demand.
Furosemide Prices in Europe
- In Germany, the Furosemide Price Index fell in Q4 2025, influenced by declining producer prices.
- Furosemide production costs decreased in December 2025 as the Producer Price Index declined by 2.5% year-over-year.
- Demand for Furosemide was supported by robust healthcare investment and pharmaceutical sector growth in Q4 2025.
- The Manufacturing Index contracted in December 2025, indicating a slowdown in overall economic activity.
- Industrial production modestly increased by 0.8% in October 2025, reflecting a stable manufacturing base.
- Retail sales grew by 1.1% in November 2025, indicating healthy consumer spending supporting healthcare affordability.
- Unemployment rate stood at 6.2% in December 2025, suggesting economic slack and pressure on healthcare access.
- Consumer prices remained stable with CPI at 1.8% in December 2025, supporting patient affordability for Furosemide.
- Natural gas prices, a key feedstock, showed a slight downward trend in Q4 2025, easing cost pressures.
Why did the price of Furosemide change in December 2025 in Europe?
- Producer Price Index declined by 2.5% in December 2025, lowering Furosemide manufacturing input costs.
- Manufacturing activity contracted in December 2025, signaling economic slowdown impacting Furosemide demand.
- Elevated energy and raw material costs throughout 2025 influenced Furosemide production expenses.
For the Quarter Ending September 2025
Furosemide Prices in North America
- In United States, Furosemide Price Index rose in Q3 2025, due to increased production costs and strong pharmaceutical demand.
- Furosemide production costs increased in Q3 2025, as CPI rose 3.0% (September 2025) and PPI climbed 2.6% (August 2025).
- Furosemide demand outlook strengthened in Q3 2025, supported by a 5.42% rise in retail sales in September 2025.
- Chemical industry inventories, including raw materials for Furosemide, shrank during Q3 2025, indicating tightening supply.
- US natural gas prices, a key energy feedstock, saw an uptick in Q3 2025, rising year-over-year in September 2025.
- Industrial production increased marginally by 0.1% year-over-year in September 2025, reflecting stable overall activity.
- A low unemployment rate of 4.3% in September 2025 supported Furosemide demand by improving healthcare access.
- Consumer confidence declined to 94.2 in September 2025, signaling weakening sentiment, though essential drug demand is less impacted.
Why did the price of Furosemide change in September 2025 in North America?
- Furosemide production costs rose due to a 3.0% year-over-year CPI increase in September 2025.
- Robust consumer spending, retail sales up 5.42% year-over-year in September 2025, bolstered Furosemide demand.
- Shrinking chemical inventories in Q3 2025, including raw materials, created upward price pressure.
Furosemide Prices in APAC
- In China, the Furosemide Price Index fell quarter-over-quarter in Q3 2025, due to weakening demand and overcapacity.
- Furosemide production costs decreased in Q3 2025, influenced by a 2.3% year-on-year decline in producer prices in September 2025.
- Petrochemical feedstock costs, including benzene, dipped in Asia during Q3 2025, easing Furosemide manufacturing expenses.
- Furosemide demand faced headwinds from contracting manufacturing activity in September 2025 and overall economic slowdown.
- Despite a 6.5% year-on-year industrial production increase in September 2025, consumer confidence remained cautious at 89.6.
- China's substantial chemical overcapacity in Q3 2025, with expanding production, contributed to global Furosemide oversupply.
- Natural gas prices remained high in Q3 2025, partially offsetting declines in other Furosemide production costs.
- Retail sales grew 3.0% year-on-year in September 2025, supporting stable consumer spending on Furosemide.
- The Furosemide Price Index is forecast to remain under pressure from persistent overcapacity and softening demand in Q3 2025.
Why did the price of Furosemide change in September 2025 in APAC?
- Weakened general chemical demand and contracting manufacturing activity in September 2025 pressured Furosemide prices.
- A 2.3% year-on-year decline in producer prices and dipping petrochemical feedstock costs reduced Furosemide expenses.
- Substantial chemical overcapacity in China during Q3 2025, with expanding production, contributed to downward Furosemide price trends.
Furosemide Prices in Europe
- In Germany, the Furosemide Price Index softened quarter-over-quarter in Q3 2025, influenced by easing producer price pressures.
- Furosemide production costs faced upward pressure in Q3 2025 due to persistently high European energy prices.
- German pharmaceutical market demand strengthened in Q3 2025, supporting the Furosemide demand outlook.
- Germany's industrial production contracted by 1.0% year-on-year in September 2025, with the Manufacturing Index Contracting.
- Consumer confidence registered -23.6 in September 2025, despite a low 3.9% unemployment rate, affecting demand.
- Regional Furosemide supply faced tightening pressures in Q3 2025 due to European chemical industry restructuring.
- Consumer Price Index (CPI) rose 2.4% year-on-year in September 2025, indicating inflationary pressures on purchasing power.
- Retail sales grew by 0.8% year-on-year in September 2025, reflecting modest consumer economic stability.
Why did the price of Furosemide change in September 2025 in Europe?
- Producer Price Index (PPI) declined 1.7% year-on-year in September 2025, easing manufacturing cost pressures.
- German pharmaceutical market demand strengthened in Q3 2025, providing some upward support for prices.
- Elevated European energy prices in Q3 2025 increased key organic chemical intermediate costs.
For the Quarter Ending December 2022
North America
The market for Furosemide API in the North American region fluctuated in the fourth quarter of 2022. Prices started to rise in Q4 2022 and kept growing due to high manufacturing costs, numerous logistical problems, and rising inflation through the second month of the fourth quarter.
Growing transportation costs and port congestion at the key ports also helped to maintain the market position. Furthermore, a slowdown in API output due to rising energy prices had a favorable positive effect on the market situation. Later in December, prices started to drop as a result of weakening inflation and declining end-user sector demand as the festival season drew near. The settlement price for Furosemide API dropped to USD 80425/MT CFR in Los Angeles in December.
Asia
The fourth quarter of 2022 saw a tumultuous trajectory for the Asia Pacific Furosemide API market. It was stated at the beginning of Q4 2022 that rising end-user sector demand, a number of logistical difficulties, and rising inflation would cause prices to increase during the second month of the quarter. Due to rising production costs driven by rising energy prices and increased domestic production to fill demands from domestic and international markets, the market remained competitive. The strict zero covid regulations and frequent lockdowns in the Chinese regions have had an effect on the market. However, because domestic stores had enough supplies on hand later in December, Furosemide API prices did start to fall. However, because domestic retailers had enough supplies on hand later in December, furosemide prices did start to fall. The softening of the policies and the underwhelming downstream demand also contributed to the market's continued downturn. The settlement price for Furosemide API dropped to USD 75325/MT FOB Shanghai in December.
Europe
Prices for Furosemide API in the European region fluctuated in the fourth quarter of 2022. The demand for Furosemide API in the pharmaceutical industry's downstream market was seen to be stable. In the first two months of Q4 022, price increases were caused by the European region's continuous port congestion and supply disruption. Increased freight costs also had an impact on the trajectory of the API for furosemide. Because of the impending Christmas season and the need to prepare for it, European retailers have decided to restock their inventory significantly. However, due to a decline in inflation, relief from port congestion, and a little increase in domestic merchant stocks, prices fell significantly in the month of December. The cost of Furosemide API was USD 82515/MT CFR Hamburg toward the end of Q4 2022.
